FY2025 · period end Dec '25 · from the 10-K filed Feb 26, 2026
Data as filed with the SEC, provided for information only — not investment advice.
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0.10B | $0.07B | $0.07B | $0.08B | $0.12B |
| Gross Profit | $0.06B | $0.05B | $0.04B | — | — |
| Operating Income | negative: -$0.02B | negative: -$0.00B | negative: -$0.02B | negative: -$0.01B | negative: -$0.04B |
| Net Income | negative: -$0.00B | negative: -$0.02B | negative: -$0.07B | negative: -$0.14B | negative: -$0.01B |
| EPS (Diluted) | negative: -$0.10 | negative: -$0.44 | negative: -$1.55 | negative: -$3.25 | negative: -$0.23 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $0.41B | $0.40B | $0.41B | $0.45B | $0.55B |
| Total Liabilities | $0.03B | $0.05B | $0.08B | $0.09B | $0.08B |
| Stockholders' Equity | $0.37B | $0.35B | $0.34B | $0.36B | $0.48B |
| Cash & Equivalents | $0.03B | $0.09B | $0.03B | $0.02B | $0.07B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $0.02B | $0.01B | negative: -$0.01B | negative: -$0.01B | negative: -$0.00B |
| Capital Expenditures | $0.01B | $0.00B | $0.01B | $0.01B | $0.01B |
| Free Cash Flow | $0.01B | $0.01B | negative: -$0.02B | negative: -$0.02B | negative: -$0.01B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 64.6% | 67.1% | 60.7% | — | — |
| Operating Margin | negative: -0.2% | negative: -0.1% | negative: -0.5% | negative: -0.1% | negative: -29.5% |
| Net Margin | negative: -0.0% | negative: -0.3% | negative: -0.5% | negative: -1.8% | negative: -7.5% |
| Return on Equity | negative: -1.3% | negative: -5.9% | negative: -18.9% | negative: -33.2% | negative: -1.9% |
| Return on Assets | negative: -1.1% | negative: -5.0% | negative: -15.4% | negative: -27.8% | negative: -1.6% |
| Debt / Equity | 0.01× | 0.05× | 0.07× | 0.07× | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or full history back to 1993 plus the smart-money dataset and webhooks on Institutional.
Who is buying and selling BIOLIFE SOLUTIONS INC — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on BLFS yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on BLFS and publish the result to your public profile.
Ask about BIOLIFE SOLUTIONS INC
Continue in Workspace — cited answers on BLFS, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate, with delisted companies kept in.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001628280-26-054355 | Jun 30, 2026 | Aug 6, 2026 | Aug 6, 2026 20:22 UTC | EDGAR |
| 10-Q | 0001628280-26-032148 | Mar 31, 2026 | May 7, 2026 | May 7, 2026 20:18 UTC | EDGAR |
| 10-K/Aamend | 0001628280-26-028012 | Dec 31, 2025 | Apr 28, 2026 | Apr 28, 2026 21:12 UTC | EDGAR |
| 10-K | 0001628280-26-012294 | Dec 31, 2025 | Feb 26, 2026 | Feb 26, 2026 21:15 UTC | EDGAR |
| 10-Q | 0001628280-25-050190 | Sep 30, 2025 | Nov 6, 2025 | Nov 6, 2025 21:17 UTC | EDGAR |
| 10-Q | 0000834365-25-000016 | Jun 30, 2025 | Aug 7, 2025 | Aug 7, 2025 20:22 UTC | EDGAR |
| 10-Q | 0001628280-25-023833 | Mar 31, 2025 | May 8, 2025 | May 8, 2025 20:20 UTC | EDGAR |
| 10-K/Aamend | 0001628280-25-017079 | Dec 31, 2024 | Apr 8, 2025 | Apr 8, 2025 20:34 UTC | EDGAR |
| 10-K | 0001628280-25-009511 | Dec 31, 2024 | Mar 3, 2025 | Mar 3, 2025 22:20 UTC | EDGAR |
| 10-Q | 0001628280-24-047178 | Sep 30, 2024 | Nov 12, 2024 | Nov 12, 2024 21:22 UTC | EDGAR |
| 10-Q | 0001628280-24-036470 | Jun 30, 2024 | Aug 9, 2024 | Aug 9, 2024 20:07 UTC | EDGAR |
| 10-Q | 0001628280-24-022690 | Mar 31, 2024 | May 10, 2024 | May 10, 2024 21:11 UTC | EDGAR |
Direct links to SEC EDGAR. BLFS has additional filings available on the SEC site.
6 numbers BIOLIFE SOLUTIONS INC later changed — same XBRL tag, both filings linked.
Liabilities·As of Mar 31, 2018
Major restatementwas$1.8M
Revised up in a 10-K.
Liabilities·As of Jun 30, 2019
Major restatementwas$5.5M
Revised up in a 10-K.
Liabilities·As of Sep 30, 2019
Major restatementwas$7.3M
Revised up in a 10-K.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q2 2019
Major restatementwas$838K
Revised up in a 10-Q.
Net Income (Loss) Attributable to Parent·Q2 2019
Major restatementwas$838K
Revised up in a 10-Q. Any P/E built on the original was 80.3% too high.
Net Income (Loss) Available to Common Stockholders, Basic·Q2 2019
Major restatementwas$838K
Revised up in a 10-Q.
BLFS is not the only one.
See every restatement we've found across the market — or get an alert the next time BLFS revises a number.
Restatements are detected by comparing every vintage of a fact across all of BIOLIFE SOLUTIONS INC's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows BLFS's most significant revisions, and a figure absent from it has not been certified as unrevised.
